The sale caps a difficult time for zilovertamab and ONCT-808 under Oncternal’s ownership. Zilovertamab was deprioritised by ...

Proposals for drug exclusivities and feeble measures to combat drug shortages are unlikely to boost innovation, say some experts.

AbbVie gains control of an in vivo CAR-T therapy that could overcome limitations with currently approved autologous ...

The FDA has approved Takeda’s new immunoglobulin therapy, Gammagard liquid ERC [immune globulin infusion (human)], to treat ...